Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity

@inproceedings{Liang2016HepaticAC,
  title={Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity},
  author={Yan Ying Liang and Z Li and Sebastian Liang and Yong Li and Ligang Yang and Minghua Lu and Hongwei Gu and Nansong Xia},
  booktitle={Nutrition & Diabetes},
  year={2016}
}
Objective:Recent studies have demonstrated that adenylate cyclase 3 (AC3) has a protective role in obesity. This gene resides at the pathway with glucagon-like peptide (GLP)-1. Liraglutide is a GLP-1 analog and has independent glucose and body weight (BW)-reducing effects. In the present study, we aimed to examine whether hepatic AC3 activity was regulated by Liraglutide and to further understand the effect of AC3 in reduction of BW and insulin resistance.Subjects:The diabesity and obese mice… CONTINUE READING
BETA
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients

Gian Paolo Fadini, Natalino Simioni, +4 authors Angelo Avogaro
  • Acta Diabetologica
  • 2013

Diabesity: an overview of a rising epidemic.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011

Similar Papers

Loading similar papers…